Entering October is the strongest period of the year for three-month returns, and shorter-term returns are also some of the best. Here we take a look at 30 dividend stocks in the S&P 500 that have ...

AbbVie's high-growth investment thesis is undeniable indeed, despite Humira's painful patent expiry and the erosion observed in its sales thus far. Our optimism arises from Skyrizi's/Rinvoq's promi...

ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.

Dividend sustainability trumps high yields when selecting stocks for passive income. The featured companies span diverse sectors including healthcare, consumer goods, retail, finance, and real estate.

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.

- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. - Biologics Lic...

AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

As a dividend growth investor focused on income, I recommend raising cash and selling lower-quality stocks due to potential recession risks. Historical data shows that rate cuts often precede reces...

NORTH CHICAGO, Ill. , Sept. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted...

AstraZeneca and AbbVie outperformed the benchmark S&P 500 index over the past three-year, five-year, and 10-year periods. AbbVie offers a relatively high yield due to declining sales of its former ...

AbbVie (ABBV) closed at $193.45 in the latest trading session, marking a -1.16% move from the prior day.

Analyzing the board of directors is a quick way to assess people power. Scientific advisory boards are easier to analyze than they might seem.

AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection.

Investing in dividend stocks allows you to earn dividend income, the best passive income stream. In August, we (my wife and I) received a dividend income total of $1,415.47. 2023 was up 24%. Eight ...